Answer
Keytruda (pembrolizumab) is contraindicated in patients with hypersensitivity to pembrolizumab or any of the excipients listed in section 6.1.
Sources for this answer
- KEYTRUDA 25 mg/mL concentrate for solution for infusionMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.3 Contraindications · Version 67Document updated
Sources checked